PuSH - Publication Server of Helmholtz Zentrum München

Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab.

Acta Derm.-Venereol. 96, 72-76 (2016)
Publishers Version DOI
Open Access Gold
Creative Commons Lizenzvertrag
as soon as is submitted to ZB.
Patients with atopic dermatitis (AD) tend to have greatly elevated levels of serum immunoglobulin E (IgE). However, the role of IgE in the pathogenesis of AD is debated. This investigator-initiated open-label pilot study evaluates an anti-IgE-treatment approach by combining extracorporeal immunoadsorption and anti-IgE antibody omalizumab in 10 patients with severe, therapy-refractory AD. IgE levels decreased after immunoadsorption and decreased continuously in all patients during anti-IgE therapy. The reverse trend was observed during 6 months follow-up without treatment. In parallel with these observations, an improvement in AD was observed during the treatment period, with aggravation during follow-up. Further research is needed, based on the principle of reducing IgE levels in order to improve clinical symptoms, using a combination anti-IgE treatment approach, adjusted according to IgE levels.
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Atopic Dermatitis ; Atopic Eczema ; Immunoglobulin E ; Ige ; Immunoadsorption ; Omalizumab ; Anti-ige-treatment; Activation-regulated Chemokine; Food Allergy; Liver-transplantation; Therapy; Disease; Urticaria; Efficacy; Thymus
Reviewing status